James L. Abbruzzese
ORCID: 0000-0001-9223-2965Also affiliated with Duke Cancer Institute
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 8 papers. Top paper: “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial”.
Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more
Dan Wang, Yongde Luo, Liang‐Hao Hu, Ya‐Wei Bi, Jun‐Tao Ji +12 more
Xiaokun Li, Jianjia Ma, James L. Abbruzzese, Weiqin Lu, Yongde Luo
Jun‐Tao Ji, Jianjia Ma, Dan Wang, Muyun Liu, James Xianxing Du +8 more
Donald P. Lesslie, Nikolas A. Dallas, Serk In Park, Marjorie Johnson, Nila U. Parikh +6 more
Tania Moccia, Cihui Zhu, Genni Paradiso, Alfredo Budillon, Paul J. Chiao +3 more
Danwen Qian, Hongliang Liu, James L. Abbruzzese, Sheng Luo, Kyle M. Walsh +2 more
Tania Moccia, Cihui Zhu, Genni Paradiso, Alfredo Budillon, Paul J. Chiao +3 more